Barinthus Biotherapeutics plc. 8-K

What Happened
Barinthus Biotherapeutics plc filed an 8-K on April 22, 2026, announcing that its board appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Mr. Swirsky, age 56, has 25+ years of experience, most recently serving as CFO of MaxCyte, Inc. (Mar 2023–Mar 2026) and previously as CFO/Treasurer of AavantiBio (Feb 2021–Dec 2022). He is a CPA (Maryland), a CFA charterholder, and holds a B.S. from Boston University and an M.B.A. from Northwestern’s Kellogg School.

Key Details

• Appointment effective date: May 1, 2026; 8-K filed April 22, 2026.
• Compensation/structure: Company entered into a master services agreement with Grand Strand BioAdvisors LLC (Mr. Swirsky is a Managing Member); fee of $20,000 per month.
• Protections: MSA provides for directors’ and officers’ liability insurance and customary indemnification for services.
• No family relationships or reportable related-party arrangements under Item 404(a) of Regulation S‑K.

Why It Matters
A new CFO and principal accounting officer means the person responsible for the company’s financial reporting and controls will change; investors should note the management change and the consulting (MSA) arrangement rather than a direct employment contract. The monthly fee, D&O coverage, and indemnification are disclosed terms that clarify the commercial and legal framework for his service. The filing states there are no related-party conflicts disclosed, which is relevant to governance and oversight.